This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10 C46 (C46.0 skin, C46.1 soft tissue, C46.2 palate, C46.3 lymph nodes, C46.4 gastrointestinal tract, C46.5 lung, C46.7 other sites, C46.9 unspecified) |
| B. Synonyms | Kaposi sarcoma, AIDS-related Kaposi sarcoma, classic Kaposi sarcoma, iatrogenic Kaposi sarcoma, endemic Kaposi sarcoma |
| C. Adult onset | Very high — occurs mainly in adults; AIDS-related KS in people in their 20s–50s; classic KS in older adults in their 60s–70s |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| 1. History | First described by Moritz Kaposi (1872); surged with the AIDS epidemic in 1981 — an HIV/AIDS-defining illness; discovery of KSHV/HHV-8 (1994) |
| 2. Causes | KSHV (HHV-8) is the necessary cause; HIV (cofactor in AIDS-related KS); immunosuppression (post-transplant KS); regional distribution (Africa) |
| 3. Genetics | KSHV latent genes (LANA, vCyclin, vFLIP); PIK3CA; VEGFR overexpression; vIL-6; persistent NF-κB activation; KSHV vGPCR |
| 4. Epidemiology | Risk more than 1,000-fold higher in HIV-positive individuals; most common in sub-Saharan Africa; very rare in Korea; decreased after the introduction of HAART |
| 5. Pathophysiology | KSHV infection → latency → vCyclin/vFLIP → spindle cell transformation; HIV Tat → VEGF stimulation → vascular proliferation |
| 6. Symptoms | Violaceous patches/nodules of the skin; oral lesions; lymphedema; dyspnea and hemoptysis (pulmonary KS); gastrointestinal bleeding |
| 7. Signs | Purple skin patches and nodules; palatal lesions; lymphadenopathy; hepatomegaly; findings of pulmonary infiltration on auscultation |
| 8. Screening | No standard screening test; regular full-body skin examination in HIV-positive individuals; KSHV serologic testing; CD4+ count monitoring |
| 9. Diagnosis | Clinical diagnosis of skin lesions + tissue biopsy; HHV-8 IHC (LANA-1); CD31, CD34; endoscopy (gastrointestinal KS); CT/PET-CT (lung and internal organs) |
| 10. Treatment | HAART (first-line, most important); liposomal doxorubicin (PLD); paclitaxel; pomponide (topical); radiation; bevacizumab under investigation |
| 11. Prognosis | Favorable after HIV control; under 3 years in the pre-HAART era; currently, objective response rate of 78% with HAART+PLD; poor with visceral involvement |
| 12. Prevention | HIV prevention (condoms, PrEP); early initiation of HAART; minimizing immunosuppression after transplantation; prevention of KSHV infection; safe sexual practices |
| 13. References | Literature: Kaposi 1872, Chang 1994 discovery of KSHV, Blood (ASH), JCO clinical studies of liposomal doxorubicin |
Kaposi sarcoma (KS) is a multifocal angioproliferative tumor originating from vascular or lymphatic endothelial cells; it was first reported in 1872 by the Hungarian-born Austrian dermatologist Moritz Kaposi, who described five cases under the title "idiopathic multiple pigmented sarcoma of the skin."
Initially, Kaposi sarcoma was regarded as a rare disease found mainly in the Mediterranean, Eastern Europe, and Africa. Its characteristic form was slowly progressing skin lesions on the lower limbs of older men of Mediterranean and Eastern European origin (classic KS), with a relatively benign course. A more aggressive form (endemic KS) occurred in Central Africa, and severe forms with prominent lymph node involvement were also reported in children.
With the AIDS epidemic, the history of Kaposi sarcoma entered an entirely new phase. In 1981, the CDC report of clusters of Kaposi sarcoma with unexplained immunodeficiency in young homosexual men in Los Angeles, USA, was the first official epidemiological report of AIDS and the first clinical description of AIDS-related KS. As the AIDS epidemic spread rapidly in the 1980s, AIDS-related KS (epidemic KS) also surged worldwide.
The discovery of KSHV (Kaposi Sarcoma-associated Herpesvirus, HHV-8) came in 1994 when Yuan Chang and Patrick Moore found a novel herpesvirus sequence in Kaposi sarcoma tissue, which became a turning point in fully understanding the pathogenesis of Kaposi sarcoma. It was established that KSHV is not a necessary and sufficient causal agent of Kaposi sarcoma but a necessary but not sufficient one. Subsequently, with the introduction of highly active antiretroviral therapy (HAART), immune function in AIDS patients recovered, and the incidence of and deaths from AIDS-related KS declined dramatically.
Infection with KSHV (HHV-8) is a necessary condition for the development of Kaposi sarcoma. Kaposi sarcoma does not develop without KSHV, and KSHV is detected in all forms of KS.
Kaposi sarcoma is divided into four clinical types according to immune status:
| Clinical type | Patient group | Features |
|---|---|---|
| Classic KS | Older men from Eastern Europe and the Mediterranean | Slow skin lesions of the lower limbs; benign course |
| Endemic KS | Sub-Saharan Africa | Both children and adults; unrelated to HIV; aggressive |
| AIDS-related (Epidemic KS) | HIV-positive individuals | Systemic and multifocal; visceral involvement common |
| Iatrogenic KS | Immunosuppression after organ transplantation | Improves when immunosuppression is stopped |
HIV is not a direct cause of KS but an important cofactor. The decrease in CD4+ T cells and impaired immune function caused by HIV infection weaken immune surveillance against KSHV and promote the development of KS. In addition, the HIV Tat protein stimulates secretion of VEGF and other growth factors, promoting the growth of KS spindle cells. The risk of KS in HIV-positive individuals is about 1,000 times or more higher than in HIV-negative individuals.
The risk of KS increases in patients receiving immunosuppressive therapy after kidney, liver, or heart transplantation. The risk is particularly high in KSHV-seropositive transplant recipients, and an association with cyclosporine use has been reported. Spontaneous regression sometimes occurs when immunosuppressants are reduced or discontinued.
KSHV maintains latent infection in host cells, and latent genes play a key role in tumor formation:
vGPCR (viral G protein-coupled receptor) is expressed during KSHV lytic replication and is a key oncogenic element that stimulates VEGF secretion, promoting vascular proliferation and tumor angiogenesis. vIL-6 (viral IL-6) activates the STAT3 pathway through the IL-6 receptor, supporting tumor cell survival and proliferation.
In KS spindle cells, PIK3CA variants, overexpression of VEGFR (VEGFR-2, VEGFR-3), and persistent NF-κB activation are found. These pathways are potential targets for mTOR inhibitors (everolimus, rapamycin) and VEGFR inhibitors (pazopanib, bevacizumab).
The incidence of Kaposi sarcoma is closely linked to the prevalence of HIV infection. Before the introduction of HAART (1980s–1990s), KS developed in about 40% of AIDS patients, but after the introduction of HAART, the incidence of AIDS-related KS decreased markedly.
Regionally, KS incidence is highest in sub-Saharan Africa, where both endemic KS and HIV-related KS account for high proportions. In some African countries in particular, KS is the first or second leading cause of cancer death in men. In the Mediterranean and Eastern Europe, classic KS occurs rarely in older men. In the United States and Europe, AIDS-KS incidence fell by 80–90% after the introduction of HAART.
KS is very rare in Korea. Because the number of people with HIV is relatively small and KSHV seroprevalence is low, KS is rare, and most cases occur in HIV-positive individuals. A small number of cases of post-transplant iatrogenic KS have also been reported.
KS shows markedly higher incidence in men than in women (more than 10:1 in AIDS-KS) and occurs mainly in adults in their 20s–50s. Classic KS occurs in older men in their 60s–70s.
KSHV is transmitted mainly through saliva, sexual contact, and blood. After infection, it remains latent within host cells, and KS does not develop when immune function is normal. However, when immune function declines (HIV infection, immunosuppressive therapy, aging), latent infection increases and cellular transformation occurs.
The characteristic pathological finding of KS is the spindle cell. These cells originate from vascular or lymphatic endothelial cells and have characteristics of transformation by KSHV latent genes. Cell cycle promotion by vCyclin, NF-κB activation and inhibition of apoptosis by vFLIP, and p53/pRb inhibition by LANA act together to cause abnormal proliferation of spindle cells.
vGPCR expression and overexpression of VEGF and VEGFR-2 promote vascular proliferation and tumor angiogenesis. Abnormalities of cell-surface adhesion molecules such as CD44 and integrins also contribute to tumor cell migration and invasion. In HIV-infected patients, the HIV Tat protein stimulates secretion of VEGF and other growth factors, accelerating the growth of KS spindle cells. Cytokines such as IL-6, IL-8, and RANTES maintain a chronic inflammatory environment that contributes to tumor promotion.
On skin examination, multiple purple to brown patches and nodules are found. Lesions can occur anywhere, including the face, limbs, trunk, soles, palms, and mucosa. Early patch lesions can be confused with bruises or hemangiomas. On oral examination, purple lesions of the palate are a typical finding of KS in AIDS patients.
Lymphadenopathy may be found, and the lymph nodes themselves may be involved by KS. Hepatomegaly and splenomegaly suggest visceral involvement. With pulmonary KS, crackles and wheezes may be heard on auscultation, and hypoxemia is observed. Gastrointestinal KS is identified by a positive fecal occult blood test and characteristic purple lesions on endoscopy.
In HIV-positive KS patients, the CD4+ T-cell count is often markedly decreased (<200 cells/μL), and KS follows a more aggressive course when HIV RNA viremia is high. Opportunistic infections (Pneumocystis pneumonia, cytomegalovirus infection, etc.) frequently coexist.
There is no standard population-based screening test for Kaposi sarcoma. However, regular surveillance is recommended in the following high-risk groups:
It is important to recognize the characteristic clinical findings of KS (purple skin lesions, oral KS) early and, when new skin lesions develop in HIV-positive individuals, to consider KS immediately and perform a biopsy.
A clinical diagnosis is possible from typical clinical findings (multiple purple skin lesions in an HIV-positive individual), but the definitive diagnosis is made by tissue biopsy. Skin biopsy is performed as a punch biopsy (3–4 mm); histologically, slit-like vascular spaces, extravasated red blood cells, and macrophage infiltration between fascicles of spindle cells are characteristic.
Immunohistochemical markers central to the diagnosis of KS:
Gastrointestinal KS is identified as characteristic purple raised lesions on upper and lower gastrointestinal endoscopy, which also allows tissue sampling. Pulmonary KS shows nodules and infiltrates distributed along the bronchovascular bundles on chest CT and is confirmed by bronchoscopic biopsy. CT or PET-CT is used to evaluate the extent of visceral involvement and to monitor treatment response.
Measurement of CD4+ T-cell count and HIV viremia is essential in AIDS-KS. KSHV infection is confirmed by serum KSHV antibody testing (anti-LANA IgG). Liver function tests and hematologic tests are used to assess the extent of visceral involvement.
The most important first-line treatment in AIDS-related KS is HAART (highly active antiretroviral therapy). When HAART suppresses HIV viremia and restores CD4+ T-cell counts, KS lesions often regress spontaneously through improved immune function. HAART alone sometimes leads to complete remission, and in mild KS a strategy of starting HAART alone and observing the course for 3–6 months is used.
Pegylated liposomal doxorubicin (PLD) is the standard chemotherapy for AIDS-KS. When given concurrently with HAART, the objective response rate is excellent at about 78% (complete remission 40%, partial remission 38%). It is preferred over standard doxorubicin because of less cardiotoxicity and myelosuppression. It is usually given every 3 weeks, and responses are durable.
Radiation therapy (RT) is effective for a small number of localized skin lesions. Retinoid (alitretinoin) gel is used for localized cutaneous KS. Cryotherapy, laser therapy, and intralesional vinblastine injection are also used for small lesions.
The prognosis of Kaposi sarcoma varies greatly with clinical type, HIV status, visceral involvement, and CD4+ count.
| Clinical situation | Prognosis |
|---|---|
| AIDS-KS, before the introduction of HAART | Median survival under 3 years; months to 1 year with visceral involvement |
| AIDS-KS, HAART+PLD treatment | Objective response rate 78%; long-term survival possible |
| Classic KS (good general condition) | Survival of years to decades; death from causes other than cancer |
| Post-transplant KS (with reduced immunosuppression) | Spontaneous regression possible after reducing immunosuppression |
| AIDS-KS with pulmonary/visceral involvement | Months without treatment; may improve with treatment |
Combined HAART and PLD treatment has markedly improved the prognosis of AIDS-KS. The higher the CD4+ T-cell count and the lower the viremia, the better the prognosis. Long-term survival is possible in the absence of visceral involvement. Classic KS progresses very slowly, so death from other causes is more common.